CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., today announced publication in a peer-reviewed journal of new data that further establish ghrelin, a potent, naturally occurring hormone, as a master regulator of metabolism. The data describe an array of physical and metabolic improvements in mice genetically engineered to lack the receptor for ghrelin (“knockout” mice), despite their having been fed a high-fat diet. These findings provide additional support for Elixir’s small molecule, oral ghrelin antagonist as a potential treatment for type 2 diabetes and other metabolic diseases.
